JP2022515193A5 - - Google Patents
Info
- Publication number
- JP2022515193A5 JP2022515193A5 JP2021536024A JP2021536024A JP2022515193A5 JP 2022515193 A5 JP2022515193 A5 JP 2022515193A5 JP 2021536024 A JP2021536024 A JP 2021536024A JP 2021536024 A JP2021536024 A JP 2021536024A JP 2022515193 A5 JP2022515193 A5 JP 2022515193A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- nucleotide
- app
- double
- rnai
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024090554A JP2024113043A (ja) | 2018-12-19 | 2024-06-04 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781774P | 2018-12-19 | 2018-12-19 | |
| US62/781,774 | 2018-12-19 | ||
| US201962862472P | 2019-06-17 | 2019-06-17 | |
| US62/862,472 | 2019-06-17 | ||
| US201962928795P | 2019-10-31 | 2019-10-31 | |
| US62/928,795 | 2019-10-31 | ||
| PCT/US2019/067449 WO2020132227A2 (en) | 2018-12-19 | 2019-12-19 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090554A Division JP2024113043A (ja) | 2018-12-19 | 2024-06-04 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515193A JP2022515193A (ja) | 2022-02-17 |
| JP2022515193A5 true JP2022515193A5 (cg-RX-API-DMAC7.html) | 2022-12-26 |
Family
ID=71101909
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536024A Pending JP2022515193A (ja) | 2018-12-19 | 2019-12-19 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
| JP2024090554A Pending JP2024113043A (ja) | 2018-12-19 | 2024-06-04 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090554A Pending JP2024113043A (ja) | 2018-12-19 | 2024-06-04 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
Country Status (20)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2854880B1 (en) | 2012-05-29 | 2019-03-13 | 3M Innovative Properties Company | Absorbent article comprising polymeric foam |
| WO2019169243A1 (en) | 2018-03-02 | 2019-09-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-beta precursor protein |
| BR112021002440A2 (pt) | 2018-08-10 | 2021-05-04 | University Of Massachusetts | oligonucleotídeos modificados visando snps |
| WO2021012082A1 (zh) * | 2019-07-19 | 2021-01-28 | 莫丁丁 | β—淀粉样蛋白环状核糖核酸、多肽及其应用 |
| JP2019213978A (ja) * | 2019-09-30 | 2019-12-19 | 株式会社三洋物産 | 遊技機 |
| MX2023001222A (es) | 2020-07-28 | 2023-04-26 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de app. |
| US20240294906A1 (en) * | 2020-07-29 | 2024-09-05 | Alnylam Pharmaceuticals, Inc. | Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases |
| WO2022165172A1 (en) * | 2021-01-29 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing amyloid precursor protein (app) |
| US20240175028A1 (en) * | 2021-03-05 | 2024-05-30 | Alnylam Pharmaceuticals, Inc | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA |
| JP2024518564A (ja) * | 2021-05-11 | 2024-05-01 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 中枢神経系のニューロンを標的とするための脂質コンジュゲーション |
| WO2023283403A2 (en) * | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
| JP2024534961A (ja) * | 2021-09-10 | 2024-09-26 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 拡大したエンドソームによって特徴付けられる疾患を処置または予防するためのAPP iRNA組成物およびその使用方法 |
| KR20240067943A (ko) | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| JP2024542125A (ja) * | 2021-10-28 | 2024-11-13 | ザ・ホンコン・ユニバーシティー・オブ・サイエンス・アンド・テクノロジー | アミロイド病変に対する治療アプローチとしてのapp発現のcrispr媒介性操作 |
| WO2023081500A2 (en) * | 2021-11-08 | 2023-05-11 | Dicerna Pharmaceuticals, Inc. | RNAi OLIGONUCLEOTIDE CONJUGATES |
| TW202335674A (zh) * | 2021-11-05 | 2023-09-16 | 美商黛瑟納製藥公司 | 靶定中樞神經系統的星狀細胞之脂質結合物 |
| TW202340462A (zh) * | 2021-11-05 | 2023-10-16 | 美商黛瑟納製藥公司 | 靶定中樞神經系統的寡樹突細胞之脂質結合物 |
| US20230392146A1 (en) * | 2022-03-11 | 2023-12-07 | University Of Massachusetts | Oligonucleotides for app modulation |
| WO2023207615A1 (zh) * | 2022-04-26 | 2023-11-02 | 南京明德新药研发有限公司 | 一类含由天然核苷酸组成突出端的双链RNAi化合物 |
| WO2023224979A1 (en) * | 2022-05-16 | 2023-11-23 | University Of Massachusetts | Optimized sirna scaffolds |
| WO2023230465A1 (en) * | 2022-05-23 | 2023-11-30 | Switch Therapeutics Inc. | Antisense oligonucleotides |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
| WO2025007961A1 (zh) | 2023-07-06 | 2025-01-09 | 大睿生物 | 调控AGT表达的dsRNA分子 |
| US20250064958A1 (en) * | 2023-08-22 | 2025-02-27 | Eli Lilly And Company | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS |
| WO2025045195A1 (zh) * | 2023-08-31 | 2025-03-06 | 上海拓界生物医药科技有限公司 | 靶向APP的RNAi剂及其医药用途 |
| CN120077136A (zh) * | 2023-09-28 | 2025-05-30 | 广州必贝特医药股份有限公司 | 抑制淀粉样前体蛋白(APP)基因表达的siRNA、药物及其应用 |
| TW202516009A (zh) * | 2023-10-10 | 2025-04-16 | 大陸商上海舶望製藥有限公司 | 抑制澱粉樣前體蛋白(app)表達的組合物和方法 |
| WO2025228429A1 (zh) * | 2024-04-30 | 2025-11-06 | 北京安龙生物医药有限公司 | 靶向淀粉样前体蛋白基因的寡核苷酸及其用途 |
| CN118979036B (zh) * | 2024-08-01 | 2025-08-19 | 北京尧景基因技术有限公司 | 抑制APP基因表达的siRNA及其缀合物和应用 |
| CN121175422A (zh) * | 2024-10-08 | 2025-12-19 | 北京安龙生物医药有限公司 | 修饰的双链寡核苷酸及其缀合物和组合物 |
| WO2026085164A2 (en) | 2024-10-16 | 2026-04-23 | Alnylam Pharmaceuticals, Inc. | Snca irna formulations and methods of use thereof |
| WO2026092658A2 (en) * | 2024-10-31 | 2026-05-07 | Sanegene Bio Usa Inc. | Small interfering rna targeting amyloid beta precursor protein (app) and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| US20080032942A1 (en) * | 2000-08-30 | 2008-02-07 | Mcswiggen James | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| CA2489174C (en) | 2002-07-10 | 2013-02-05 | Thomas Tuschl | Rna-interference by single-stranded rna molecules |
| US7851615B2 (en) * | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| CA2528963A1 (en) * | 2003-06-27 | 2005-01-13 | Sirna Therapeutics, Inc. | Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
| GB0324854D0 (en) * | 2003-10-24 | 2003-11-26 | Expresson Biosystems Ltd | App/ena antisense |
| EP2239328A3 (en) * | 2005-08-18 | 2011-01-05 | Alnylam Pharmaceuticals Inc. | Methods and compositions for treating neurological disease |
| JP5252622B2 (ja) * | 2007-01-17 | 2013-07-31 | 独立行政法人産業技術総合研究所 | 高いヌクレアーゼ耐性と優れたrna干渉効果を発現可能な二本鎖rna |
| WO2009113579A1 (ja) * | 2008-03-11 | 2009-09-17 | 学校法人埼玉医科大学 | 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬 |
| WO2011072091A1 (en) * | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| US20130253168A1 (en) * | 2010-08-31 | 2013-09-26 | Steven L. Colletti | Novel single chemical entities and methods for delivery of oligonucleotides |
| US9127274B2 (en) * | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| US9663784B2 (en) * | 2012-05-26 | 2017-05-30 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
| BR112015013105B1 (pt) * | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
| US10004814B2 (en) * | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| TWI864340B (zh) * | 2014-10-10 | 2024-12-01 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| TWI769565B (zh) * | 2014-11-10 | 2022-07-01 | 美商阿尼拉製藥公司 | B型肝炎病毒(HBV)iRNA組成物及其用途方法 |
| EP3362562B1 (en) * | 2015-10-16 | 2026-07-22 | Academisch Ziekenhuis Leiden, also acting under the name Leiden University Medical Centre (LUMC) | Antisense oligonucleotides for use in treating alzheimer's disease |
| CA3098623A1 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| JP7557469B2 (ja) * | 2019-01-29 | 2024-09-27 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Appの発現を低減するための化合物及び方法 |
| EP3983077A4 (en) * | 2019-06-17 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM |
-
2019
- 2019-12-19 AU AU2019405783A patent/AU2019405783B2/en active Active
- 2019-12-19 TW TW108146697A patent/TW202039844A/zh unknown
- 2019-12-19 EP EP19900781.6A patent/EP3898979A4/en active Pending
- 2019-12-19 MX MX2021007570A patent/MX2021007570A/es unknown
- 2019-12-19 JP JP2021536024A patent/JP2022515193A/ja active Pending
- 2019-12-19 SG SG11202105886QA patent/SG11202105886QA/en unknown
- 2019-12-19 PE PE2021000927A patent/PE20211420A1/es unknown
- 2019-12-19 BR BR112021011895-0A patent/BR112021011895A2/pt unknown
- 2019-12-19 CN CN201980092566.2A patent/CN113454222B/zh active Active
- 2019-12-19 KR KR1020217022070A patent/KR20210111780A/ko active Pending
- 2019-12-19 CR CR20210393A patent/CR20210393A/es unknown
- 2019-12-19 MY MYPI2021003429A patent/MY206230A/en unknown
- 2019-12-19 CN CN202510065418.9A patent/CN120041447A/zh active Pending
- 2019-12-19 WO PCT/US2019/067449 patent/WO2020132227A2/en not_active Ceased
- 2019-12-19 CA CA3124090A patent/CA3124090A1/en active Pending
- 2019-12-19 PH PH1/2021/551482A patent/PH12021551482A1/en unknown
-
2020
- 2020-07-09 US US16/925,286 patent/US11034957B2/en active Active
-
2021
- 2021-05-07 US US17/314,909 patent/US20220002724A1/en active Pending
- 2021-06-09 IL IL283852A patent/IL283852A/en unknown
- 2021-06-17 CL CL2021001605A patent/CL2021001605A1/es unknown
- 2021-06-18 DO DO2021000126A patent/DOP2021000126A/es unknown
- 2021-07-14 CO CONC2021/0009163A patent/CO2021009163A2/es unknown
-
2024
- 2024-06-04 JP JP2024090554A patent/JP2024113043A/ja active Pending
-
2025
- 2025-09-18 DO DO2025000233A patent/DOP2025000233A/es unknown
-
2026
- 2026-06-15 AU AU2026204572A patent/AU2026204572A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113454222B (zh) | 淀粉样前体蛋白(APP)RNAi剂组成物及其使用方法 | |
| TWI727917B (zh) | TMPRSS6iRNA 組成物及其使用方法 | |
| CN115397436B (zh) | 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 | |
| JP7863095B2 (ja) | Snca関連神経変性疾患を治療又は予防するためのsnca irna組成物及びその使用方法 | |
| TW201726148A (zh) | 治療serpinc1相關疾患之方法及組成物 | |
| TW201718855A (zh) | 甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關疾病之使用方法 | |
| EA035756B1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
| KR20220069103A (ko) | 최소 플루오린 함량을 갖는 작은 간섭 rna의 화학적 변형 | |
| JP2023523993A5 (cg-RX-API-DMAC7.html) | ||
| JP2024536811A5 (cg-RX-API-DMAC7.html) | ||
| JP2022520986A5 (cg-RX-API-DMAC7.html) | ||
| TW202132567A (zh) | 亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法 | |
| WO2023116607A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| JP2024528503A5 (cg-RX-API-DMAC7.html) | ||
| JP2023544413A5 (cg-RX-API-DMAC7.html) | ||
| JP2023511434A5 (cg-RX-API-DMAC7.html) | ||
| IL294728A (en) | lrrk2 RNA material preparations and methods of using them | |
| JP2024522068A5 (cg-RX-API-DMAC7.html) | ||
| TW202400193A (zh) | 抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法 | |
| TW202305134A (zh) | 杭丁頓蛋白(HTT)iRNA劑組成物及其使用方法 | |
| JP2024521907A5 (cg-RX-API-DMAC7.html) | ||
| TW202330920A (zh) | 用於調節apoc3表現之組合物及方法 | |
| CN117561334A (zh) | 人染色体9开放阅读框72(C9ORF72)iRNA药剂组合物和其使用方法 | |
| KR20200127008A (ko) | 담관 부족-연관된 상태의 치료를 위한 방법 및 조성물 | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 |